Welcome to our dedicated page for Instil Bio news (Ticker: TIL), a resource for investors and traders seeking the latest updates and insights on Instil Bio stock.
Instil Bio, Inc. (Nasdaq: TIL) is a clinical-stage biopharmaceutical company whose news flow centers on the development of novel therapies, with a particular focus on its lead asset AXN-2510, a PD-L1xVEGF bispecific antibody in development for multiple solid tumors. Company press releases and related SEC filings provide regular updates on clinical progress, collaborations, and financial results.
News about Instil Bio frequently covers clinical trial milestones for AXN-2510/IMM2510, including Phase 1 monotherapy studies in relapsed or refractory solid tumors and data from Phase 1 and Phase 2 studies in non-small cell lung cancer (NSCLC) conducted by ImmuneOnco Biopharmaceuticals (Shanghai) Inc. in China. These updates have included preliminary safety and efficacy data, such as objective response rates and partial response rates in squamous and non-squamous NSCLC, as well as safety profiles in front-line NSCLC when ’2510 is combined with chemotherapy.
Investors and observers can also find corporate and financial updates in Instil Bio’s news, including quarterly financial results, operating expense details, and explanations of non-GAAP financial measures. Announcements have highlighted research and development spending, general and administrative expenses, and restructuring and impairment charges, along with reconciliations of GAAP to non-GAAP net loss and net loss per share.
Additional news items describe collaborations and corporate developments, such as the relationship with ImmuneOnco around ’2510, the role of Axion Bio, Inc. as a wholly-owned subsidiary dedicated to AXN-2510, leadership appointments including a Chief Medical Officer and board additions, and participation in healthcare conferences and investor events focused on the PD-(L)1xVEGF bispecific antibody landscape.
By following Instil Bio news, readers can track ongoing disclosures about AXN-2510’s clinical development, evolving collaboration arrangements, and the company’s financial and strategic updates as it advances its clinical-stage pipeline.
Instil Bio (NASDAQ: TIL) has confirmed a cash runway extending beyond 2026, following a consolidation of R&D operations in Manchester, UK. The company anticipates initiating its ITIL-306 phase 1 study in the second half of 2023, pending Clinical Trial Application clearance from the UK MHRA, and expects initial clinical data in 2024. For Q4 2022, Instil reported a net loss of $53.8 million, with total cash and equivalents of $260.9 million as of December 31, 2022. Research and development expenses decreased to $20.7 million from $42.6 million in Q4 2021, while general and administrative expenses increased to $12.9 million compared to $11.2 million in the same quarter last year.
Instil Bio (NASDAQ: TIL) announced plans to reduce its US workforce by approximately 15 employees, consolidating manufacturing and Phase 1 clinical trials for its CoStAR-TIL™ therapy to Manchester, U.K.. This strategic move is anticipated to extend the company's cash runway beyond 2026. Initial clinical data from the ITIL-306 program is expected in 2023. The company is also evaluating the sale or sublease of its Tarzana manufacturing site to further improve cash resources. CEO Bronson Crouch expressed confidence in the Manchester team's capabilities and the prospects of their TIL therapies.
Instil Bio has resumed its Phase 1 trial of ITIL-306 for non-small cell lung cancer, ovarian cancer, and renal cell carcinoma after a voluntary pause. The company implemented additional quality safeguards in the manufacturing process. Initial data readout is expected in 2023 at a medical conference. Instil anticipates a cash runway extending into 2025, excluding potential financing from its Tarzana manufacturing site. The focus remains on developing next-generation tumor infiltrating lymphocyte therapies.
FAQ
What is the current stock price of Instil Bio (TIL)?
What is the market cap of Instil Bio (TIL)?
